Topical Formulation Development

Topical formulation development focuses on designing drug products that are delivered directly to the skin or mucosal surfaces. It’s critical for ensuring optimal absorption, stability, and patient usability, particularly in dermatology research, inflammation research, and aesthetic indications in which local delivery drives efficacy.

As part of Symbio’s therapeutically focused clinical research model, DDL supports programs from early formulation through clinical supply manufacturing. This includes IND, NDA, and ANDA-enabling activities that help sponsors move efficiently from concept to clinic with a single, integrated partner.

DDL develops a wide range of topical products, including creams, gels, ointments, solutions, and suspensions supporting both small molecules and complex modalities like peptides, proteins, and oligonucleotides.

Topical therapies must balance skin penetration, tolerability, and formulation stability, all while addressing complex inflammatory pathways. DDL’s experience in topical development ensures formulations are designed with both clinical performance and patient experience in mind.

Yes. DDL provides GMP manufacturing, clinical packaging, labeling, and global distribution, supporting seamless trial execution across multiple regions and study phases.

DDL operates as an FDA-registered, cGMP-compliant facility, following quality by design principles. Combined with Symbio’s expertise in indication-specific clinical research, this ensures regulatory readiness and consistent product quality throughout development.

Absolutely. While topical formulation development is often central to dermatology and aesthetics research, DDL’s broader expertise expands to ophthalmic product development.